Detalhe da pesquisa
1.
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Breast Cancer Res Treat;
158(3): 485-95, 2016 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27393622
2.
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Ann Oncol;
24(8): 2011-6, 2013 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23613476
3.
Bcl-XL protects cancer cells from p53-mediated apoptosis.
Oncogene;
11(7): 1389-94, 1995 Oct 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-7478561